BRAF and non-small cell lung carcinoma: The discovery of activating BRAF mutations, particularly the V600E variant, marked a significant milestone in oncology by identifying critical drivers of tumorigenesis in NSCLC, where they represent a rare but important oncogenic alteration found in approximately 2–4% of cases (16).